整合素αvβ6和JunB在口腔鳞癌组织中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2015.03.016

Abstract

Abstract:

OBJECTIVE: This study aimed to investigate the expression of integrin αvβ6 and JunB in oral squamous cell carcinoma (OSCC) and the correlation with clinicopathologic characteristics and prognosis. METHODS:The expression of integrin αvβ6 and JunB protein was detected with immunohistochemical staining assay in 120 cases of OSCC and 15 samples of normal oral mucosa. The correlation with clinicopathologic characteristics and prognosis of the patients were evaluated. RESULTS:Integrin αvβ6 was detected in both cytoplasm and cellular membrane of OSCC, but JunB protein was localized in the nuclei of both OSCC and normal oral mucous tissues. The expressions of integrin αvβ6 and JunB protein in OSCC were significantly higher than that in normal oral mucosa (P<0.01). The expression of integrin αvβ6 was positively related to depth of invasion(T stage), tumor differentiation degree and lymph node metastasis(N stage) (P<0.05). The expression of JunB was positively related to depth of invasion and lymph node metastasis (P<0.05). Survival as a single factor analysis revealed that patients with over-expression of integrin αvβ6 had a shorter overall survival(OC) (P=0.021). Through Cox multivariate regression analysis, lymph node metastasis (N stage) was an independent risk factor that affected the prognosis. CONCLUSION: The over-expressions of integrin αvβ6 and JunB were common in OSCC and closely correlated with tumor invasion and metastasis. Integrin αvβ6 may be used as a prognostic marker for therapy.

Key words: integrin αvβ6, oral squamous cell carcinoma, JunB, immunohistochemistry

CLC Number:

R394.3

FANG Shaobin, DENG Xiaoling, CHEN Jun, CHEN Yonghui, XU Mingyan. The expression and clinical relevance of integrin αvβ6 and JunB in oral squamous cell carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(3): 234-238,241.

References

[1] Scully C, Bagan J. Oral squamous cell carcinoma overview[J]. Oral Oncol, 2009, 45(4):301-308.
[2] Lippman SM, Sudbø J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development[J]. J Clin Oncol, 2005, 23(2):346-356.
[3] De Vicente JC, Lequerica-Fernández P, Santamaria J, et al. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis[J]. J Oral Pathol Med, 2007, 36(7):415-424.
[4] Thomas G, Nyström M, Marshall J. αvβ6 integrin in wound healing and cancer of the oral cavity[J]. J Oral Pathol Med, 2006, 35(1):1-10.
[5] Jochum W, Passegué E, Wagner EF. AP-1 in mouse development and tumorigenesis[J]. Oncogene, 2001, 20(19):2401-2412.
[6] Nausch N, Florin L, Hartenstein B, et al. Cutting edge:the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1ε[J]. J Immunol, 2006, 176(1):7-11.
[7] Sullivan BP, Kassel KM, Manley S, et al. Regulation of transforming growth factor-β1-dependent integrin β6 expression by p38 mitogen-activated protein kinase in bile duct epithelial cells[J]. J Pharmacol Exp Ther, 2011, 337(2):471-478.
[8] Li HX, Zheng JH, Fan HX, et al. Expression of αvβ6 integrin and collagen fibre in oral squamous cell carcinoma:association with clinical outcomes and prognostic implications[J]. J Oral Pathol Med, 2013, 42(7):547-556.
[9] Hamidi S, Salo T, Kainulainen T, et al. Expression of αvβ6 integrin in oral leukoplakia[J]. Br J Cancer, 2000, 82(8):1433.
[10] Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma[J]. J Clin Invest, 2005, 115(2):339.
[11] Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB[J]. EMBO J, 2002, 21(15):4104-4113.
[12] Rassidakis GZ, Thomaides A, Atwell C, et al. JunB expression is a common feature of CD30+;lymphomas and lymphomatoid papulosis[J]. Mod Pathol, 2005, 18(10):1365-1370.
[13] Bossy-Wetzel E, Bravo R, Hanahan D. Transcription factors junB and c-jun are selectively up-regulated and functionally implicated in fibrosarcoma development[J]. Genes Dev, 1992, 6(12a):2340-2351.
[14] Santaguida M, Schepers K, King B, et al. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal[J]. Cancer Cell, 2009, 15(4):341-352.
[15] Chang YS, Yeh KT, Yang MY, et al. Abnormal expression of JunB gene in hepatocellular carcinoma[J]. Oncol Rep, 2005, 13(3):433-438.
[16] Langer S, Singer C, Hudelist G, et al. Jun and Fos family protein expression in human breast cancer:correlation of protein expression and clinicopathological parameters[J]. Eur J Gynaecol Oncol, 2005, 27(4):345-352.
[17] Koo A, Chiu R, Soong J, et al. The expression of C-jun and JunB mRNA in renal cell cancer and in vitro regulation by transforming growth factor beta 1 and tumor necrosis factor alpha 1[J]. J Urol, 1992, 148(4):1314-1318.
[18] Kowalski LP, Bagietto R, Lara JR, et al. Prognostic significance of the distribution of neck node metastasis from oral carcinoma[J]. Head Neck, 2000, 22(3):207-214.
[19] Noguchi M, Kido Y, Kubota H, et al. Prognostic factors and relative risk for survival in N1-3 oral squamous cell carcinoma:a multivariate analysis using Cox's hazard model [J]. Br J Oral Maxillofac Surg, 1999, 37(6):433-437.

The expression and clinical relevance of integrin αvβ6 and JunB in oral squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[2]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[3]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.
[4]	HUANG Zhuangcheng, WANG Honghao, SHEN Peilin, LIN Ming'en, HE Xuejun. Expression and clinical significance of Notch signalingrelated proteins in cystitis glandularis and bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 374-377,383.
[5]	YANG Xingxiao, ZOU Naiyi, LI Qiaofang, ZHANG Xueyuan, SONG Heng, LIU Zhikun, MA Ming, SHAN Baoen, ZHU Shuchai. Significance in expression of RNF2 and PCNA proteins in esophageal squamous cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 254-257.
[6]	CAI Yihuang, DENG Xiaoling, HUANG Wenxia, HUANG Jie, JI Qing, XU Mingyan. Construction and identification of lentiviral knockdown plasmid pLKO.1-hSRF [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 234-238.
[7]	LI Yang, XING Long, MOHAMMED H, MA Xiaolong, XIE Fuqiang, FENG Zhenghu, CHE Yinfu. Clinicopathological significance of expression of thioredoxin and its reductase-1 in tongue squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(2): 87-91.
[8]	MA Kun, WU Haoyu, LI Peng, WANG Li, LI Baixiang. Induction of dopaminergic neuron degeneration by atrazine in substantia nigra in adolescent rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 251-255.
[9]	LIU Dezhong, CHANG Bo, LIN Feixiang, LI Xuedong. β-catenin expression in hepatocellular carcinoma and its effect on prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 300-303.
[10]	FENG Shuitu, CHEN Yide, CHEN Yuqiang, LIN Yubiao, ZHENG Wenhui. Differential expression of Gadd45α in Helicobacter Pylori-infected human gastric cancer and clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(5): 353-358,392.
[11]	ZHAI Xiaoran, JIANG Mei, ZHAO Xiaoting, GU Meng, YUE Wentao. Clinical significance of PFTK1 expression in human non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 231-235.
[12]	CHEN Guangcan, HONG Liangli, HUANG Jiexiong, XIE Aosi, GUO Dan, LIU Shuhui. Expression of GST-π and P-gp in gastric cardia cancer and their clinical significance in the Chaoshan high risk area [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 36-40.
[13]	HUANGFU Bing, PANG Wenbiao, ZHANG Ruihu, GUO Min, GAO Jiping, SONG Guohua. Development of oral buccal pouch mucosa cancer in Chinese hamsters and dynamic observation of their carcinogenesis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 56-59,65.
[14]	QIN Jiesheng, HONG Liangli, LIN Xuni, WANG Huige, QIU Qiancheng. Expression and significance of Sema4C in laryngeal squamous carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(3): 230-233.
[15]	LAN Yu, LIU Dongdong, LIN Ming'en, HONG Yingkai, HUANG Jiansheng, CHEN Si, HE Xuejun. Expression and clinical significance of silent information regulator 1 in bladder urothelial cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(2): 125-128.